Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports ⊕
found
⊕ Slightly Positive overall
0.00 negativity
0.00 neutrality
0.00 positivity
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.